Journal of Experimental Pharmacology
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Complexation of amphotericin B and curcumin with serum albumins: solubility and effect on erythrocyte membrane damage
(7467) Total Article Views
Authors: Avinash K Kudva, MN Manoj, Bale M Swamy, et al
Published Date January 2011
Volume 2011:3 Pages 1 - 6
Avinash K Kudva1, MN Manoj2, Bale M Swamy1, Candadai S Ramadoss3
1Department of Biochemistry, Karnatak University, Dharwad, India; 2Bigtec Labs, SID Entrepreneurship Centre, 3Unichem Laboratories Ltd, Biosciences R&D Centre, IISc campus, Bangalore, India
Abstract: Amphotericin and curcumin are known to form complexes with albumins individually. In-silico analysis shows that amphotericin B and curcumin have separate binding regions on human serum albumin and bovine serum albumin. The complex formed with albumin in the presence of both amphotericin and curcumin is water soluble, and it retains antifungal activity. Interestingly, it was found that the presence of curcumin in the complex significantly delayed the red cell lysis by amphotericin B, indicating the possibility of moderating the toxic side effects of the drug using curcumin. Furthermore, since the presumed ternary complex is stable and water soluble, its potential use in the treatment of visceral leishmaniasis (kala azar) and systemic fungal infections needs to be evaluated.
Keywords: hemolytic activity, antifungal activity
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Readers of this article also read:
- 27th ECNP Congress
18 - 21 October, 2014
- Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer
- Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss